Wells Fargo analyst Vik Chopra lowered the firm’s price target on Conmed (CNMD) to $57 from $70 and keeps an Equal Weight rating on the shares. The firm notes that the company reported Q1 sales and EPS beats. EPS guide was raised with Q1 beat and lower FX partly offset by 14c of tariff impact. Wells expects the stock to be up given better-than-expected tariff impact.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue